Literature DB >> 3039117

Evaluation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparison with epinine and dopamine.

A J Nichols, R R Ruffolo.   

Abstract

The alpha and beta adrenoceptor-mediated effects of the novel, orally active inotropic prodrug, ibopamine, have been studied in the pithed rat and compared with those effects mediated by dopamine and the active form of ibopamine, epinine. All three agents produced alpha adrenoceptor-mediated pressor responses in pithed rats, and the vasopressor effects of ibopamine and epinine, but not dopamine, were potentiated by beta adrenoceptor blockade with propranolol (3 mg/kg i.v.). Catecholamine depletion with reserpine (5 mg/kg i.p.) did not affect the vasoconstrictor response elicited by any of these agents, indicating a direct effect in the vasculature. Epinine was 10 times more potent than ibopamine or dopamine. The pressor response to all three agents was antagonized by the alpha-1 adrenoceptor antagonist, prazosin (0.1 mg/kg i.v.) and the alpha-2 adrenoceptor antagonist, rauwolscine (0.5 mg/kg i.v.), suggesting the involvement of both alpha adrenoceptor subtypes in the vasopressor responses elicited by these compounds. After complete blockade of alpha adrenoceptors using a combination of phenoxybenzamine (3 mg/kg i.v.), prazosin (0.1 mg/kg i.v.) and rauwolscine (1 mg/kg i.v.), higher doses of ibopamine, epinine and dopamine produced a propranolol-sensitive, beta-1 adrenoceptor-mediated positive chronotropic response that was significantly reduced in reserpine-pretreated rats, indicating a significant indirect component in the activity of these compounds at the level of the myocardium. Epinine and dopamine were equipotent and were 10 times more potent than ibopamine as directly acting beta-1 adrenoceptor agonists.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3039117

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.

Authors:  J P M Finberg; A Gross; O Bar-Am; R Friedman; Y Loboda; M B H Youdim
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

2.  Effect of epinine on tension of human renal arteries.

Authors:  R H Schwinger; C Schulz; K Brixius; M Böhm; J Müller-Ehmsen; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

Review 3.  Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  J M Henwood; P A Todd
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

4.  Epinephrine synthesis in rat skin by an N-methyltransferase.

Authors:  H Elayan; B Kennedy; M G Ziegler
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

5.  Differential cardiovascular and neuroendocrine effects of epinine and dopamine in conscious pigs before and after adrenoceptor blockade.

Authors:  L J van Woerkens; F Boomsma; A J Man in 't Veld; M M Bevers; P D Verdouw
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

6.  Lack of desensitization of alpha- and beta-adrenoceptor function during chronic treatment of healthy volunteers with ibopamine, an orally active dopamine receptor agonist.

Authors:  O E Brodde; I Klusmann; M Wojcik; A J Man in't Veld; F Boomsma; M C Michel
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Dose-dependent separation of dopaminergic and adrenergic effects of epinine in healthy volunteers.

Authors:  A Daul; M Elter-Schulz; U Poller; F Jockenhövel; K Pönicke; F Boomsma; A J Man in't Veld; R F Schäfes; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

8.  Rat renal epinephrine synthesis.

Authors:  M G Ziegler; B Kennedy; H Elayan
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

Review 9.  Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials.

Authors:  Tariq Ahmad; P Elliott Miller; Megan McCullough; Nihar R Desai; Ralph Riello; Mitchell Psotka; Michael Böhm; Larry A Allen; John R Teerlink; Giuseppe M C Rosano; Joann Lindenfeld
Journal:  Eur J Heart Fail       Date:  2019-08-13       Impact factor: 15.534

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.